Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “PITYRIASIS”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 199 records · Page 11Linked to original sources
PubMed1994

A study on the therapeutic efficacy of Cassia alata, Linn. leaf extract against Pityriasis versicolor.

The therapeutic efficacy of Cassia alata leaf extract against Pityriasis versicolor has been reported for the first time involving humans. For the collection of clinically effective antifungal compounds from the leaves of Cassia alata, a simple procedure has been devised. A 10-year human study indicates that the leaf extract can be reliably used as a herbal medicine to treat Pityriasis versicolor. The leaf extract has no side-effects.

Adolescent↗
PubMed2004

An alternative treatment for pityriasis versicolor, tinea cruris, tinea corporis and tinea faciei with topical application of honey, olive oil and beeswax mixture: an open pilot study.

OBJECTIVE: To evaluate the possible role of honey, olive oil and beeswax in the treatment of skin fungal infections. PATIENTS AND METHODS: Thirty-seven patients with pityriasis versicolor, tinea cruris, tinea corporis and tinea faciei were studied. After clinical evaluation of redness, scaling, pruritus and burning/pain sensation and mycological assessment, honey mixture containing honey, olive oil and beeswax (1:1:1) was applied to the lesions three times daily for a maximum of 4 weeks. RESULTS: Clinical response was obtained in 86% of patients with pityriasis versicolor, 78% of patients with tinea cruris and in 75% of patients with tinea corporis. Mycological cure was obtained in 75, 71 and 62% of patients with PV, tinea cruris and tinea corporis, respectively. The patient with tinea faciei showed clinical and mycological cure 3 weeks after commencement of therapy. CONCLUSION: Honey mixture may have place in the management of these skin conditions and rigorous, controlled trials are justified.

Administration, Topical↗
PubMed1984

Psoralens and ultraviolet A therapy of pityriasis lichenoides.

Three patients with long-standing pityriasis lichenoides, which was resistant to other forms of therapy, were successfully treated with PUVA (psoralens and ultraviolet light of wavelength A). One patient had complete clearing of all lesions, and the other two had marked improvement. PUVA is being used to treat increasing numbers of patients with pityriasis lichenoides, and the results have been very good.

Adult↗
PubMed2005

Sparing of the upper axillary area in pityriasis versicolor.

Increased temperature and sweating are considered factors predisposing to pityriasis versicolor. In this case report, sparing of the vaults of the axillae which are naturally occluded and sweaty areas, in a patient with widespread lesions of pityriasis versicolor is discussed. It is the second observation in this regard and further contributions are invited.

Adolescent↗
PubMed1999

Cell-mediated immunity to Malassezia furfur in patients with seborrhoeic dermatitis and pityriasis versicolor.

The lymphocyte transformation response to Malassezia furfur, Candida albicans, phytohaemagglutinin, concanavlin A and tuberculin purified protein derivative of 12 patients with pityriasis versicolor, 15 patients with seborrhoeic dermatitis and matched controls, was studied. Patients with pityriasis versicolor showed a significantly lower response to M. furfur than patients with seborrhoeic dermatitis and controls.

Adult↗
PubMed2001

Case report. Erythrasmoid pityriasis versicolor.

A 50-year-old Caucasian man with pityriasis versicolor that was localized almost exclusively in the inguinal folds and was characterized by lesions clinically superimposable on those of erythrasma is described. Due to these clinical characteristics, it is proposed that this variety of pityriasis versicolor is defined as 'erythrasmoid'.

Antifungal Agents↗
PubMed2002

Pityriasis versicolor.

UNLABELLED: Pityriasis versicolor is a common superficial fungal infection of the skin. It is caused by Malassezia spp., which are normal human saprophytes. Under certain conditions, both exogenous and endogenous, the fungus can convert from a yeast to a pathogenic mycelial form. This alteration results in mild inflammation of the skin, and in characteristic clinical and histological changes. The taxonomy of Malassezia spp. has recently been modified to include six obligatorily lipophilic species, all of which can be found on human skin, plus one non-obligatorily lipophilic species, which only rarely colonizes human hosts. LEARNING OBJECTIVES: At the conclusion of this learning activity, participants should be aware of the role of Malassezia in the development of pityriasis versicolor, the clinical and histological changes arising from this dermatosis, and the diagnosis and treatment of this disorder.

Administration, Cutaneous↗
PubMedDate not supplied

IgE antibodies to Malassezia furfur, M. sympodialis and Pityrosporum orbiculare in patients with atopic dermatitis, seborrheic eczema or pityriasis versicolor, and identification of respective allergens.

Malassezia yeasts may be a trigger factor for atopic dermatitis. Following the recent reclassification of the genus, the presence of specific IgE antibodies was examined in the sera of patients with atopic dermatitis (n = 223), pityriasis versicolor (n = 83), seborrheic eczema (n = 50) and hymenoptera allergy (n = 39) and in controls without skin diseases (n = 50). In addition to using the commercially available radioallergosorbent test (RAST) for Pityrosporum orbiculare couplings were also made against the reference strains for M. furfur and M. sympodialis. To characterize the specificity and molecular weight of corresponding epitopes identical material was used for production of an immunoblot. Despite high total levels of IgE, controls and patients with pityriasis versicolor showed no specific IgE antibodies. Six patients (12%) with seborrheic eczema were positive while 78 patients (35%) with atopic dermatitis had specific IgE antibodies in higher RAST classes that differed between the Malassezia species. The molecular weights of the main antigens of M. sympodialis and M. furfur were determined to be 15, 22, 30, 37, 40, 58, 79, 92, 99 and 124 kDa and 15, 25, 27, 43, 58, 92, 99 and 107 kDa, respectively. Evaluated according to the location of their disease, patients with head and neck lesions most frequently showed Malassezia-specific IgE antibodies. However, there were differences between the Malassezia species tested, the previously used strain P. orbiculare being assignable to the species M. sympodialis.

Adult↗
PubMed2004

Pityriasis versicolor: quality of studies.

OBJECTIVE: To evaluate the quality of the published literature on the treatment of pityriasis versicolor and to compare this evaluation with the number of times the work has been cited. METHODS: A search was performed using MEDLINE (1966-2002) to find publications evaluating the treatment of pityriasis versicolor. Two reviewers evaluated each clinical trial according to a list of pre-determined criteria including randomization and blinding, prior sample size calculation, treatment regimen clearly explained, and well-defined efficacy parameters. A maximum score of 20 could be attained by each publication. A citation count was performed using the ISI Web of Science Database (http://www.isinet.com/isi/products/citation/wos/). RESULTS: A total of 94 studies were included in this analysis of quality. Studies with a score of 8 or more were considered to be high quality, and 61 studies were rated as high-quality studies (65%). There was no significant correlation between paper quality and citation count. CONCLUSION: It is important for investigators and clinicians to be aware of the design of a high-quality protocol, since such high-quality studies are more likely to reflect accurate efficacy rates. Also, it is important for the information on the design and conduct of the trial to be conveyed to the reader so that a meaningful comparison between the studies can be made.

Bibliometrics↗
PubMedDate not supplied

Treatment of pityriasis versicolor with ketoconazole.

Eighty-two patients with pityriasis versicolor were treated orally with ketoconazole in tablet form (200 mg). The tablets were taken at least 90 min before a meal, and patients who received only one tablet daily were told to refrain from bathing except immediately before ingestion of the drug and only once a day. Dosage of ketoconazole varied from a single dose of 400 mg to 200--400 mg per day for four weeks. Seventy-seven patients reported no adverse effects. There were reports from others of headache, gastralgia, nausea, dyspnea, dizziness, or tinnitus. In most affected patients, these symptoms stopped with the first meal eaten after initiation of treatment. Follow-up examinations were performed at different intervals. The maximal therapeutic effect of ketoconazole was seen three to six weeks after initiation of therapy. Seventy-eight patients were considered cured; one had received only one tablet. Only hypopigmented macules remained. Examination of these areas with a Wood lamp revealed no fluorescence, and scrapings examined with the light microscope did not contain Malassezia furfur. These results indicate that ketoconazole is effective in the treatment of pityriasis versicolor, but the problem of protecting susceptible persons from infection and reinfection remains.

Follow-Up Studies↗
PubMedDate not supplied

Treatment of dermatophytoses and pityriasis versicolor with itraconazole.

Thirty patients (18 males and 12 females) with dermatophytoses were treated with itraconazole. Twenty-eight patients received 100 mg per day for 14 days, and two patients, one with tinea pedis and one with tinea manuum, were treated for 28 days. Thirty patients (11 males and 19 females) with pityriasis versicolor were treated with 200 mg of itraconazole. for five days. Half of the patients received the 200 mg in one dose, and the other half received 100 mg twice a day. Twenty-nine of the 30 patients with dermatophytoses were clinically and mycologically cured, and one patient was improved. All 30 patients with pityriasis versicolor experienced complete clinical and mycologic cure; no difference was noted between the two groups. Ten of the 60 patients treated reported adverse reactions to therapy. The primary adverse effects were nausea and epigastric pain; one patient had diarrhea. There were no alterations in the patients' blood biochemical values. These results suggest that itraconazole is safe and effective for the treatment of dermatomycoses.

Adolescent↗
PubMedDate not supplied

Itraconazole in pityriasis versicolor.

Forty-two patients with pityriasis versicolor were treated with itraconazole. Patients were allocated randomly to one of two groups; the first group (22 patients) received 200 mg of itraconazole per day for five days, and the second group (20 patients) received 100 mg per day for the same period. The study lasted 30 days. Each patient's clinical history was recorded before treatment. Wood's light examination was also done at this time and was repeated weekly. Direct microscopic examination of lesions was undertaken at the beginning, middle, and end of the trial. Specimens for cultures could be obtained from only 24 patients. The cure rate was 95% in the first group and 75% in the second. The difference between these rates was not significant, but the groups were small and the difference in dosage may ultimately be meaningful in terms of rates of cure. Itraconazole appears to be effective in a high percentage of cases of pityriasis versicolor.

Adult↗
PubMed2001

Comparative efficacy of ketoconazole and fluconazole in the treatment of pityriasis versicolor: a one year follow-up study.

Pityriasis versicolor can be treated by a single or multiple dosage regime of ketoconazole as well as by fluconazole. The therapeutic efficacy of these two drugs has not been compared. One hundred and eighty patients with moderate to extensive pityriasis versicolor confirmed by KOH and Wood's lamp examination were randomly assigned to one of the four oral antifungal regimes: Ketoconazole 400 mg single dose (Category I), Ketoconazole 200 mg daily for 10 days (Category II), Fluconazole 400 mg single dose (Category III) or Fluconazole 150 mg per week for 4 weeks (Category IV). Follow up was done at 2 and 4 weeks and then at 3, 6 and 12 months after the treatment in each group. KOH and Wood's lamp examinations were repeated each time. After four weeks of treatment, clinical cure was observed in 66.6% (Category I), 73.3% (Category II), 80% (Category III) and 59.9% (Category IV) of patients. Mycological cure after four weeks of treatment was observed in 53.3% (Category I), 73.3% (Category II), 82.2% (Category III) and 64.4% (Category IV) of patients. After twelve months of follow-up, maximum relapses were observed with Category I. No relapse was seen in Category III patients. The time period of relapse varied from three to ten months. In conclusion, single dose 400 mg oral fluconazole provided the best clinical as well as mycological cure rate with no relapse during twelve months of follow-up.

Administration, Oral↗
PubMed1993

The carriage of Malassezia furfur serovars A, B and C in patients with pityriasis versicolor, seborrhoeic dermatitis and controls.

The aetiological role of Malassezia furfur in various dermatoses is controversial. The role of the three serovars of M. furfur in Malassezia-associated diseases has not been investigated. This study measured population densities of M. furfur serovars A, B and C, propionibacteria and Micrococcaceae on the chest, back, forehead, left and right cheeks of 10 patients with pityriasis versicolor, and 10 age- and sex-matched controls; and 10 patients with seborrhoeic dermatitis, and 10 age- and sex-matched controls. The population densities of M. furfur, propionibacteria and Micrococcaceae did not vary at a given site between patients and the corresponding control subjects. Malassezia furfur serovar A was found to be the predominant isolate on the chest and back of all four groups, but there was no difference in the distribution of serovars on the forehead and cheeks. No serovar was specifically associated with lesional skin in either disease. Thus, this data indicated that there was no difference in either the total population density of M. furfur or the distribution of serovars on lesional skin compared with control skin in either pityriasis versicolor or seborrhoeic dermatitis.

Adult↗
PubMed1989

Pityriasis versicolor--epidemiological and therapeutical study.

Seventy-six patients with extensive pityriasis versicolor were divided into 3 groups and treated orally with ketoconazole, 200 mg daily, for 10, 20 or 30 days respectively. 50 patients out of this number completed the study. After 6 months, 46 patients were checked up. Eight of them developed relapses effectively treated with ketoconazole for another 15 days. Six out of these 8 patients belonged to the first group using ketoconazole for 20 days only. On the basis of this observation, we do not consider a 10 days' treatment to be sufficient and recommend that the patient should be treated for at least 20 days. As a preventive measure we recommend a daily bath with salicylic acid and sulphur soap. The frequency of the infection was higher in males (71.4%) than in females (28.6%). The youngest of the male patients was 4 months of age and the oldest 70 years. The youngest female was 4 months old and the oldest 50 years. Pityriasis versicolor was found to be predominant in the age group of 21--30 years. The sites most commonly involved were back, chest and the upper extremities.

Adolescent↗
PubMed1988

Pityriasis (tinea) versicolor in infancy.

Pityriasis (tinea) versicolor is a common disorder of adults. We cared for five infants (four males and one female) with the disease. Diagnosis was confirmed by potassium hydroxide preparation demonstrating the filaments of Malassezia furfur and/or Pityrosporum orbiculare, the yeast form. Three patients had lesions in the neonatal period. The mother of one baby had pityriasis versicolor. Two patients were siblings. One baby had associated atopic dermatitis and two had a positive family history of atopy.

Age Factors↗
PubMed1997

The efficacy of a topical application of terbinafine 1% solution in subjects with pityriasis versicolor: a placebo-controlled study.

A prospective randomised placebo-controlled double-blind study was designed to investigate whether topical terbinafine 1% solution is an effective treatment for subjects with pityriasis versicolor. The intention-to-treat population consisted of 110 subjects. The number of subjects who received terbinafine 1% solution was 76 and the number who received placebo was 34; treatments were given twice a day for 1 week. The primary efficacy variables were categorised at weeks 1, 2, 4 and 8. Eight weeks after the start of therapy, 81% of the subjects using terbinafine solution and 41% of those receiving placebo had a negative mycological examination (p < 0.001). A clinical effect of treatment was recorded in 72% of the subjects using terbinafine 1% solution and 26% of those receiving placebo (p < 0.001). We conclude that terbinafine 1% solution is an effective and safe local treatment modality for pityriasis versicolor.

Administration, Topical↗
PubMed1984

Comparative clinical trial of bifonazole solution versus selenium sulphide shampoo in the treatment of pityriasis versicolor.

38 patients were entered into a controlled randomised trial, comparing two forms of topical treatment for pityriasis versicolor. Diagnosis was made on clinical criteria and confirmed by direct microscopic examination of Parker Quink/KOH preparations. 20 patients were treated with bifonazole solution daily for 2 weeks. 18 patients were treated with 2.5% selenium sulphide shampoo daily for one week and weekly for six weeks. Mycological examination showed that Malassezia furfur was present in all patients prior to treatment. At the end of the trial, 1 patient (5%) treated with bifonazole and 4 patients (22%) of those treated with selenium sulphide shampoo showed the presence of the fungus in the skin. This study demonstrates that bifonazole solution is an effective and well-tolerated form of treatment for pityriasis versicolor. A 2-week course of bifonazole solution was as effective as a 7-week course of selenium sulphide shampoo in eradicating the disease and had a lower relapse rate at 4 weeks.

Administration, Topical↗